摘要
Thrombolytic therapy has been proved to be effective in treating acute myocardial infarction (AMI), whereas the role of urgent percutaneous transluminal coronary angioplasty (PTCA) is disputed. Results of many clinical trials show that urgent PTCA, comparing with intravenous thrombolytic agents, has more advantages in increasing reperfusion rate, lowering mortality, the rate of reinfarct and bleeding. PTCA has gradually become a routine option in the treatment of AMI. This review focus mainly on PTCA intervention of AMI without thrombolysis, after thrombolytic success, and after thrombolytic failure.
Thrombolytic therapy has been proved to be effective in treating acute myocardial infarction (AMI), whereas the role of urgent percutaneous transluminal coronary angioplasty (PTCA) is disputed. Results of many clinical trials show that urgent PTCA, comparing with intravenous thrombolytic agents, has more advantages in increasing reperfusion rate, lowering mortality, the rate of reinfarct and bleeding. PTCA has gradually become a routine option in the treatment of AMI. This review focus mainly on PTCA intervention of AMI without thrombolysis, after thrombolytic success, and after thrombolytic failure.
出处
《基础医学与临床》
CSCD
北大核心
2001年第2期97-100,共4页
Basic and Clinical Medicine
关键词
急性心肌梗死
介入疗法
PTCA
CABG
支架置入
acute myocardial infarction
percutaneous transluminal coronary angioplasty
thrombolytic therapy